See more : NGEx Minerals Ltd. (NGEX.V) Income Statement Analysis – Financial Results
Complete financial analysis of Oxford Cannabinoid Technologies Holdings Plc (OCTP.L) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Oxford Cannabinoid Technologies Holdings Plc, a leading company in the Biotechnology industry within the Healthcare sector.
- Bionime Corporation (4737.TW) Income Statement Analysis – Financial Results
- Babcock International Group PLC (BCKIF) Income Statement Analysis – Financial Results
- Bang & Olufsen a/s (BGOUF) Income Statement Analysis – Financial Results
- Golden Shield Resources Inc. (GSRFF) Income Statement Analysis – Financial Results
- XPS Pensions Group plc (XPS.L) Income Statement Analysis – Financial Results
Oxford Cannabinoid Technologies Holdings Plc (OCTP.L)
About Oxford Cannabinoid Technologies Holdings Plc
Oxford Cannabinoid Technologies Holdings Plc, a pharmaceutical company, engages in the research, development, and commercialization of cannabinoid-based prescription medicines. Its lead drug candidate is OCT461201, a selective CB2 receptor agonist in solid oral dosage form that is in pre-clinical development for use in the treatment of IBS-associated visceral pain, as well as neuropathic pain conditions, including post herpetic neuralgia. The company is also developing OCT130401, which is in pre-clinical development for the treatment of trigeminal neuralgia. Oxford Cannabinoid Technologies Holdings Plc was incorporated in 2017 and is headquartered in London, the United Kingdom.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 38.81K | 63.58K | 445.40K | 1.24M | 1.28M |
| Gross Profit | -38.81K | -63.58K | -445.40K | -1.24M | -1.28M |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 4.30M | 3.15M | 445.40K | 0.00 | 0.00 |
| General & Administrative | 2.67K | 2.53M | 1.52M | 1.38M | 0.00 |
| Selling & Marketing | 2.67M | 2.78M | 0.00 | 0.00 | 0.00 |
| SG&A | 2.67M | 2.79M | 1.52M | 1.38M | 0.00 |
| Other Expenses | 0.00 | 0.00 | 1.02M | 0.00 | 0.00 |
| Operating Expenses | 6.98M | 5.94M | 2.54M | 1.10M | 1.49M |
| Cost & Expenses | 7.02M | 6.00M | 2.99M | 2.35M | 2.77M |
| Interest Income | 3.84K | 0.00 | 47.02K | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 67.71K | 20.49K | 19.84K |
| Depreciation & Amortization | 38.81K | 52.06 | 164.69K | 83.01K | 1.70K |
| EBITDA | -7.00M | -5.94M | -2.77M | -1.26M | -1.28M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -7.02M | -6.00M | -3.35M | -2.35M | -2.77M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -18.75K | 1.00 | -20.69K | -6.38K | -105.45K |
| Income Before Tax | -7.03M | -6.00M | -3.37M | -2.37M | -2.88M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -1.09M | -862.97K | -138.65K | -225.73K | -261.87K |
| Net Income | -5.95M | -5.14M | -3.23M | -2.14M | -2.62M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.01 | -0.01 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | -0.01 | -0.01 | 0.00 | 0.00 | 0.00 |
| Weighted Avg Shares Out | 960.42M | 960.42M | 960.42M | 960.42M | 960.42M |
| Weighted Avg Shares Out (Dil) | 960.42M | 960.42M | 960.42M | 960.42M | 960.42M |
Source: https://incomestatements.info
Category: Stock Reports